image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 1.07
0.943 %
$ 9.5 M
Market Cap
0.92
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one BFRI stock under the worst case scenario is HIDDEN Compared to the current market price of 1.07 USD, Biofrontera Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one BFRI stock under the base case scenario is HIDDEN Compared to the current market price of 1.07 USD, Biofrontera Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one BFRI stock under the best case scenario is HIDDEN Compared to the current market price of 1.07 USD, Biofrontera Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
34.1 M REVENUE
18.82%
-22.7 M OPERATING INCOME
-1.32%
-20.1 M NET INCOME
-3045.47%
-24.9 M OPERATING CASH FLOW
-53.68%
619 K INVESTING CASH FLOW
112.01%
8.41 M FINANCING CASH FLOW
-40.01%
9.01 M REVENUE
14.96%
-4.96 M OPERATING INCOME
2.19%
-5.67 M NET INCOME
-2105.84%
-1.21 M OPERATING CASH FLOW
74.41%
0 INVESTING CASH FLOW
100.00%
-298 K FINANCING CASH FLOW
-5.64%
Balance Sheet Biofrontera Inc.
image
Current Assets 23.1 M
Cash & Short-Term Investments 1.42 M
Receivables 5.16 M
Other Current Assets 16.5 M
Non-Current Assets 4.86 M
Long-Term Investments 0
PP&E 1.75 M
Other Non-Current Assets 3.11 M
Current Liabilities 18.1 M
Accounts Payable 8.91 M
Short-Term Debt 4.6 M
Other Current Liabilities 4.59 M
Non-Current Liabilities 5.05 M
Long-Term Debt 804 K
Other Non-Current Liabilities 4.25 M
EFFICIENCY
Earnings Waterfall Biofrontera Inc.
image
Revenue 34.1 M
Cost Of Revenue 17.4 M
Gross Profit 16.6 M
Operating Expenses 39.3 M
Operating Income -22.7 M
Other Expenses -2.55 M
Net Income -20.1 M
RATIOS
48.80% GROSS MARGIN
48.80%
-66.56% OPERATING MARGIN
-66.56%
-59.09% NET MARGIN
-59.09%
-420.01% ROE
-420.01%
-72.07% ROA
-72.07%
-157.16% ROIC
-157.16%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Biofrontera Inc.
image
Net Income -20.1 M
Depreciation & Amortization 1.06 M
Capital Expenditures -5 K
Stock-Based Compensation 1.04 M
Change in Working Capital -4.39 M
Others -14.5 M
Free Cash Flow -24.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Biofrontera Inc.
image
BFRI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Biofrontera Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that a key milestone in its Phase 3 study of the use of Ameluz and RhodoLED PDT in the treatment of sBCC (ALA-BCC-CT013) was met with the last patient completing the 1 year follow-up visit in December of 2024. globenewswire.com - 3 weeks ago
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that the 100th commercial RhodoLED® XL Lamp has now been installed in the US market. globenewswire.com - 1 month ago
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the completion of a private placement of a $4.2 million senior secured convertible note (the “Note”) with its principal shareholders. globenewswire.com - 2 months ago
Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript Biofrontera Inc. (NASDAQ:BFRI ) Q3 2024 Earnings Conference Call November 14, 2024 10:00 AM ET Company Participants Andrew Barwicki - Investor Relations Hermann Luebbert - Chief Executive Officer, Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Bruce Jackson - The Benchmark Company Operator Welcome to the Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded. seekingalpha.com - 2 months ago
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $4.64 per share a year ago. zacks.com - 2 months ago
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update WOBURN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update. globenewswire.com - 2 months ago
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time. accesswire.com - 3 months ago
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of PDT, today announced top-line results in its Phase 3 study of the use of Ameluz® with the BF-RhodoLED® lamp in the treatment of sBCC (study ALA-BCC-CT013). globenewswire.com - 3 months ago
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announced today that the database for the treatment phase of study ALA-BCC-CT013 has been locked. globenewswire.com - 3 months ago
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's sNDA to increase the maximally approved dosage from one to three tubes of Ameluz® per treatment. globenewswire.com - 3 months ago
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that management will present at the 3rd Annual ROTH Healthcare Opportunities Conference to be held at the Metropolitan Club in New York, NY. Date: October 9, 2024 Time of Presentation: 12:30 - 1:10 PM ET Format: Live Presentation 1x1 Meetings: Please contact your Roth representative About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. accesswire.com - 4 months ago
Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript Biofrontera Inc. (NASDAQ:BFRI ) Q2 2024 Earnings Conference Call August 15, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - CEO, Chairman and Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera Inc. Second Quarter 2024 Financial Results and Business Update Conference Call. All participants will be in a listen-only mode. seekingalpha.com - 5 months ago
8. Profile Summary

Biofrontera Inc. BFRI

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 9.5 M
Dividend Yield 0.00%
Description Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Contact 120 Presidential Way, Woburn, MA, 01801 https://www.biofrontera.us.com
IPO Date Oct. 29, 2021
Employees 83
Officers Ms. Alycia Torres Vice President of Administration Mr. Eugene Frederick Leffler III Chief Financial Officer Ms. Erica F. Gates CPA, M.B.A. Senior Director of Finance & Principal Accounting Officer Mr. Daniel Hakansson J.D. General Counsel & Head of Compliance Dr. Hermann Luebbert Ph.D. Chief Executive Officer, President & Executive Chairman Mr. Jon Lyons M.B.A., Ph.D. Vice President of Scientific & Medical Affairs Mr. Mark Baldyga Vice President of Sales & Marketing